Our Batten disease programs are now in great hands with Tern Therapeutics. We look forward to following their advancement and impact on the CLN2 community.
Tern Therapeutics is excited to announce its launch and financing: https://lnkd.in/e5WvwDn4
REGENXBIO Inc.
Biotechnology Research
Rockville, Maryland 32,492 followers
Seeking to improve lives through the curative potential of gene therapy.
Über uns
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
- Website
-
https://www.regenxbio.com
External link for REGENXBIO Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- Rockville, Maryland
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2008
- Spezialitäten
- Biotechnology, Biopharmaceuticals, and Gene Therapy
Standorte
-
Primäre
Wegbeschreibung erhalten
9804 Medical Center Dr
Rockville, Maryland 20850, US
Employees at REGENXBIO Inc.
Aktualisierungen
-
Today, we announced that we will be sharing data from our RGX-121 program for the treatment of MPS II, also known as Hunter syndrome, at the SSIEM 2024 Annual Symposium. Learn more: https://lnkd.in/etZq_qKJ #SSIEM2024
-
-
Today is Women’s Equality Day! Established in 1973, this day commemorates the passage of the 19th Amendment, granting women the constitutional right to vote in the United States. Today, Women’s Equality Day goes beyond suffrage, celebrating the full equality of women in all aspects of life, including the workplace. We are proud that women represent more than half of our team, leading advancements in the lab, in the clinic and across REGENXBIO.
-
-
At REGENXBIO, two of our core values are innovation and perseverance – both incredibly important in advancing the science of gene therapy. Hear from Ayda Mayer, Executive Director, Vector Core, as she reflects on how our approach to science and innovation makes REGENXBIO unique.
-
-
Our team was pleased to participate in CureDuchenne’s family workshop in Minneapolis this past weekend. Heartfelt thanks to CureDuchenne for their commitment to supporting and educating the Duchenne community.
-
-
REGENXBIO’s Culture Club, formed in 2016, is a cross-functional team dedicated to leading events that connect us, give back to the community, and foster our amazing culture. Most recently, our Culture Club hosted its first plant swap! At REGENXBIO, we recognize that our team members have a diverse array of hobbies and interests outside of the office – thank you to the Culture Club for creating opportunities to share them.
-
-
Thank you to the Reagan-Udall Foundation for the FDA for bringing together stakeholders, including regulators, patient advocates and industry, to discuss the important role of biomarkers in developing new therapies for rare disease. Read the report summarizing these discussions and learn more about the unmet need for patients with neuronopathic MPS.
Read pages 2 and 3 of our “Qualifying Biomarkers to Support Rare Disease Regulatory Pathways” workshop summary to gain a better understanding of neuronopathic mucopolysaccharidoses (MPS) from the perspective of a health professional and an MPS parent: https://lnkd.in/ePdxb2NY Denali Therapeutics Orchard Therapeutics - U.S. REGENXBIO Inc. Ultragenyx
-
-
REGENXBIO will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Learn more: https://lnkd.in/ewyq9NF9
-
-
REGENXBIO reports second quarter 2024 financial results and recent operational highlights. Learn more: https://lnkd.in/euU4K35a
-
-
REGENXBIO announces new positive data from AFFINITY DUCHENNE trial of RGX-202. Learn more: https://lnkd.in/ezeGvvFC
-
Ähnliche Seiten
Jobs durchsuchen
Aktie
RGNX
NASDAQ
20 Minuten Verzögerung
$11.76
0.15 (1.292%)
- Öffnen Sie
- 11.55
- Niedrig
- 11.22
- Hoch
- 11.78
Daten von Refinitiv
Siehe mehr Informationen aufFinanzierung
REGENXBIO Inc.
10 total rounds
Siehe mehr Informationen auf crunchbase
Letzte Runde
Eigenkapital nach dem IPO
Externer Crunchbase Link für die letzte Finanzierungsrunde
US$ 140.0M